Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Citius Oncology (CTXR) details early LYMPHIR launch uptake and $400M CTCL market
Citius Oncology, a subsidiary of Citius Pharmaceuticals (CTXR), reported positive early commercial progress for LYMPHIR, a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), estimating an initial market exceeding $400 million. The company highlighted growing formulary adoption in oncology centers, expanding payer coverage, and repeat orders, alongside advancing clinical development through academic collaborations for other lymphoma and solid tumors. Key safety concerns for LYMPHIR include capillary leak syndrome, infusion-related reactions, hepatotoxicity, visual impairment, and embryo-fetal toxicity.